EU: EMA does not authorize the drug Leqembi against Alzheimer’s

2024-08-05 22:25:32

EU: EMA does not authorize the drug Leqembi against Alzheimer’s

The Committee for Medicinal Products for Human Use of the EMA (European Medicines Agency) has recommended not to grant a marketing authorization for Leqembi (lecanemab), a drug intended for the treatment of Alzheimer’s disease.

The committee noted that the observed effect of Leqembi in delaying cognitive decline does not outweigh the risk of serious side events associated with the drug, in particular the frequent appearance of amyloid-related imaging abnormalities (Aria) , with swelling and excessive bleeding in the brain. of patients receiving Leqembi.